Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16979200 | 0.96 | CYP2C9 (0.41) | CYP2C9OPRL1ALDH1A1LMNAMAPT | |
| SCHEMBL16979233 | 0.95 | OPRL1 (0.36) | CYP2C9OPRL1ALDH1A1LMNAMAPT | |
| SCHEMBL16979207 | 0.92 | CYP2C9 (0.40) | CYP2C9OPRL1ALDH1A1LMNAMAPT | |
| SCHEMBL16979149 | 0.88 | CYP2C9 (0.42) | CYP2C9OPRL1ALDH1A1LMNAMAPT | |
| SCHEMBL16983392 | 0.86 | CYP2C9 (0.38) | CYP2C9OPRL1ALDH1A1LMNAMAPT | |
| SCHEMBL16983275 | 0.85 | CYP2C9 (0.37) | CYP2C9OPRL1ALDH1A1LMNAMAPT | |
| SCHEMBL16983394 | 0.85 | CYP2C9 (0.37) | CYP2C9OPRL1ALDH1A1LMNAMAPT | |
| SCHEMBL16979241 | 0.84 | OPRL1 (0.36) | CYP2C9OPRL1MAPTNOTUMMEN1 | |
| SCHEMBL16979234 | 0.84 | CYP2C9 (0.34) | CYP2C9ALDH1A1LMNAMAPTTLR4 | |
| SCHEMBL16983506 | 0.83 | CYP2C9 (0.35) | CYP2C9OPRL1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783481-B2 | Carbonyl derivative, liquid crystal composition containing compound thereof and liquid crystal display device | JNC CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-9783481-B2 | Carbonyl derivative, liquid crystal composition containing compound thereof and liquid crystal display device | JNC CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| US-20150218452-A1 | CARBONYL DERIVATIVE, LIQUID CRYSTAL COMPOSITION CONTAINING COMPOUND THEREOF AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218452-A1 | CARBONYL DERIVATIVE, LIQUID CRYSTAL COMPOSITION CONTAINING COMPOUND THEREOF AND LIQUID CRYSTAL DISPLAY DEVICE | RCC2, RCC1, ROCK2 | CYP2C9 1928/4885OPRL1 2767/4885ALDH1A1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.